Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Chronic Leukemia

Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC)

Bone Marrow Transplantation volume 49, pages 756–760 (2014)Cite this article

Subjects

Abstract

Progression of Philadelphia-negative myeloproliferative (MPN) or myelodysplastic/myeloproliferative neoplasms (MDS/MPN) to acute myeloid leukemia (AML) is an adverse event in the course of the disease. Although allogeneic hematopoietic SCT (allo-SCT) is considered as the only curative therapy, few data exist on the outcome of patients with Philadelphia-negative MPN or MDS/MPN in blast phase who received an allo-SCT. Sixty patients were included in this retrospective study. AML was secondary to an MPN in 43 cases, whereas AML evolved from an MDS/MPN in 17 cases. Patients received allo-SCT in CR or advanced disease in 26 cases and 34 cases, respectively. With a median follow-up of 31 months (range, 25–44), OS and leukemia-free survival (LFS) were, respectively, 18% and 9% at 3 years. CR at transplant was associated with an improved LFS in univariate and multivariate analysis. The 3-year LFS was 18% for patients undergoing allo-SCT in CR versus 3% in advanced disease (P=0.008). Absence of thrombosis and an intermediate or favorable AML karyotype were associated with an improved outcome for patients who received allo-SCT in CR. New strategies are needed to improve the outcome of patients with MPN–MDS/MPN in blast phase.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Bjorkholm M, Derolf AR, Hultcrantz M, Kristinsson SY, Ekstrand C, Goldin LR et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol 2011; 29: 2410–2415.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Tam CS, Nussenzveig RM, Popat U, Bueso-Ramos CE, Thomas DA, Cortes JA et al. The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms. Blood 2008; 112: 1628–1637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Thepot S, Itzykson R, Seegers V, Raffoux E, Quesnel B, Chait Y et al. Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM). Blood 116: 3735–3742.

    Article  CAS  PubMed  Google Scholar 

  4. Courville EL, Wu Y, Kourda J, Roth CG, Brockmann J, Muzikansky A et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol 2013; 26: 751–761.

    Article  PubMed  Google Scholar 

  5. Koh Y, Kim I, Bae JY, Song EY, Kim HK, Yoon SS et al. Prognosis of secondary acute myeloid leukemia is affected by the type of the preceding hematologic disorders and the presence of trisomy 8. Jpn J Clin Oncol 2010; 40: 1037–1045.

    Article  PubMed  Google Scholar 

  6. Cherington C, Slack JL, Leis J, Adams RH, Reeder CB, Mikhael JR et al. Allogeneic stem cell transplantation for myeloproliferative neoplasm in blast phase. Leuk Res 2012; 36: 1147–1151.

    Article  PubMed  Google Scholar 

  7. Kennedy JA, Atenafu EG, Messner HA, Craddock KJ, Brandwein JM, Lipton JH et al. Treatment outcomes following leukemic transformation in Philadelphia-negative myeloproliferative neoplasms. Blood 2013; 121: 2725–2733.

    Article  CAS  PubMed  Google Scholar 

  8. Mesa RA, Li CY, Ketterling RP, Schroeder GS, Knudson RA, Tefferi A . Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005; 105: 973–977.

    Article  CAS  PubMed  Google Scholar 

  9. Ciurea SO, de Lima M, Giralt S, Saliba R, Bueso-Ramos C, Andersson BS et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation. Biol Blood Marrow Transplant 2010; 16: 555–559.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Alchalby H, Zabelina T, Stubig T, van Biezen A, Bornhauser M, Di Bartolomeo P et al. Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation: a study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 2014; 20: 279–281.

    Article  PubMed  Google Scholar 

  11. Vardiman JW, Harris NL, Brunning RD . The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292–2302.

    Article  CAS  PubMed  Google Scholar 

  12. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.

    Article  CAS  PubMed  Google Scholar 

  13. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322–2333.

    CAS  PubMed  Google Scholar 

  14. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner T, Burnett AK et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010; 115: 453–474.

    Article  PubMed  Google Scholar 

  15. Klein JP, Rizzo JD, Zhang MJ, Keiding N . Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part I: unadjusted analysis. Bone Marrow Transplant 2001; 28: 909–915.

    Article  CAS  PubMed  Google Scholar 

  16. Scrucca L, Santucci A, Aversa F . Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant 2007; 40: 381–387.

    Article  CAS  PubMed  Google Scholar 

  17. Kundranda MN, Tibes R, Mesa RA . Transformation of a chronic myeloproliferative neoplasm to acute myelogenous leukemia: does anything work? Curr Hematol Malig Rep 7: 78–86.

    Article  Google Scholar 

  18. Robin M, Tabrizi R, Mohty M, Furst S, Michallet M, Bay JO et al. Allogeneic haematopoietic stem cell transplantation for myelofibrosis: a report of the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Br J Haematol 152: 331–339.

    Article  PubMed  Google Scholar 

  19. Eghtedar A, Verstovsek S, Estrov Z, Burger J, Cortes J, Bivins C et al. Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia. Blood 2012; 119: 4614–4618.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Mascarenhas J, Heaney ML, Najfeld V, Hexner E, Abdel-Wahab O, Rampal R et al. Proposed criteria for response assessment in patients treated in clinical trials for myeloproliferative neoplasms in blast phase (MPN-BP): formal recommendations from the post-myeloproliferative neoplasm acute myeloid leukemia consortium. Leuk Res 2012; 36: 1500–1504.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

We would like to thank Nicole Raus for data management.

Author information

Authors and Affiliations

  1. Hématologie Clinique, CHU Rennes, Hôpital Pontchaillou, Rennes, France

    X Cahu

  2. Hématologie Clinique, CHU Nantes, Hôtel Dieu, Nantes, France

    P Chevallier

  3. Hématologie Clinique, CHU Angers, Angers, France

    A Clavert

  4. Hématologie Adulte, Hôpital Necker, AP-HP, Paris, France

    F Suarez

  5. Hématologie Clinique, Hospices Civils de Lyon, Lyon, France

    M Michallet

  6. Hématologie Adulte, Hopital Saint-Eloi, Montpellier, France

    L Vincent

  7. Service d' Hématologie, Hôpital Haut Levêque, Pessac, France

    S Vigouroux

  8. Service de Greffe de moelle, Institut Paoli Calmettes, Marseille, France

    D Blaise

  9. Clinique Universitaire d'Hématologie, CHU Grenoble, France

    C Mariette

  10. Hématologie Clinique, Hôpital de Hautepierre, CHU Strasbourg, France

    K Bilger

  11. Service d'Hématologie-greffe, Hôpital Saint-Louis, AP-HP, Paris, France

    M Robin & R Peffault de Latour

  12. Hématologie Clinique, Hôpital Claude Huriez, Lille, France

    I Yakoub-Agha

  13. Hématologie Clinique, Hôpital Saint Antoine, AP-HP, Paris, France

    M Mohty

Authors
  1. X Cahu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Chevallier
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A Clavert
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. F Suarez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M Michallet
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. L Vincent
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Vigouroux
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. D Blaise
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. C Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. K Bilger
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M Robin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. I Yakoub-Agha
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. R Peffault de Latour
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. M Mohty
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M Mohty.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Bone Marrow Transplantation website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cahu, X., Chevallier, P., Clavert, A. et al. Allo-SCT for Philadelphia-negative myeloproliferative neoplasms in blast phase: a study from the Societe Française de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant 49, 756–760 (2014). https://doi.org/10.1038/bmt.2014.31

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2014.31

This article is cited by

Search

Advanced search

Quick links